Affinity Asset Advisors’s NewAmsterdam Pharma NAMS Stock Holding History

Affinity Asset Advisors’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.32M	Hold	275,000	–	–	0.42%	61
2026 Q1	$8.8M	Hold	275,000	–	–	0.45%	56
2025 Q4	$9.65M	Hold	275,000	–	–	0.55%	45
2025 Q3	$7.82M	Hold	275,000	–	–	0.68%	40
2025 Q2	$4.98M	Sell	275,000 -50,000	-15%	-$912K	0.68%	41
2025 Q1	$6.65M	Sell	325,000 -100,000	-24%	-$2.22M	0.63%	35
2024 Q4	$10.9M	Sell	425,000 -47,390	-10%	-$1.01M	1.46%	24
2024 Q3	$7.84M	Buy	472,390 +49,235	+12%	+$852K	1.07%	30
2024 Q2	$8.13M	Buy	423,155 +136,955	+48%	+$2.75M	0.94%	33
2024 Q1	$6.77M	Buy	286,200 +161,200	+129%	+$3.27M	0.84%	36
2023 Q4	$1.4M	Hold	125,000	–	–	0.26%	63
2023 Q3	$1.16M	Buy	125,000 +25,000	+25%	+$271K	0.33%	54
2023 Q2	$1.19M	Buy	+100,000	New	+$1.33M	0.42%	47

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Affinity Asset Advisors's NAMS Position: Q2 2026 in Review

Affinity Asset Advisors held its NewAmsterdam Pharma (NAMS) position steady in Q2 2026 at 275,000 shares worth $9.32M. The position accounts for 0.42% of the portfolio, ranked #61.

Affinity Asset Advisors first reported a position in NAMS in Q2 2023 and has held it in 13 quarters since. The position peaked at $10.9M in Q4 2024. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Affinity Asset Advisors held 275,000 shares of NewAmsterdam Pharma worth $9.32M as of Q2 2026.
Affinity Asset Advisors left its NewAmsterdam Pharma share count unchanged in Q2 2026.
NewAmsterdam Pharma made up 0.42% of Affinity Asset Advisors's portfolio in Q2 2026, its #61 holding.
Affinity Asset Advisors first reported a position in NewAmsterdam Pharma in Q2 2023 and has held it in 13 quarters since.
Affinity Asset Advisors's NewAmsterdam Pharma position peaked at $10.9M in Q4 2024.
194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.